Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
A phase 1/2 trial of Palacaparib, Temozolomide, Trastuzumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.
Overview
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT05417594 by AstraZeneca, with 695 participants planned, started 2022-06-24 and due to reach its primary completion in 2028-02-07. Interventions recorded: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd) and Datopotamab Deruxtecan (Dato-DXd).
Similar pages
not linked directly; found by shared links- TrialA Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Shares Datopotamab deruxtecan, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab, Trastuzumab deruxtecan, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialNBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Shares Temozolomide, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
Shares Temozolomide, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Shares Datopotamab deruxtecan, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Trastuzumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Trastuzumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialEIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Shares Trastuzumab deruxtecan, Metastatic cancer (cancer that has spread) and the tag pipeline.